Corbus Pharmaceuticals Holdings logo

Corbus Pharmaceuticals HoldingsNASDAQ: CRBP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 October 2014

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$203.78 M
-72%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-98%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:30:43 GMT
$16.92+$0.71(+4.38%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CRBP Latest News

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
globenewswire.com29 October 2024 Sentiment: POSITIVE

NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.

Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
zacks.com26 August 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
globenewswire.com20 August 2024 Sentiment: POSITIVE

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
zacks.com09 August 2024 Sentiment: POSITIVE

Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
zacks.com09 August 2024 Sentiment: POSITIVE

The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
globenewswire.com06 August 2024 Sentiment: NEUTRAL

NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
globenewswire.com30 July 2024 Sentiment: POSITIVE

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.

Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet
investorplace.com30 June 2024 Sentiment: POSITIVE

Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate  and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.

These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
InvestorPlace19 April 2024 Sentiment: POSITIVE

Small-cap stocks have historically shown better performance compared to larger stocks. After a period of lagging performance, it seemed like small-cap stocks were poised to make a comeback.

What type of business is Corbus Pharmaceuticals Holdings?

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

What sector is Corbus Pharmaceuticals Holdings in?

Corbus Pharmaceuticals Holdings is in the Healthcare sector

What industry is Corbus Pharmaceuticals Holdings in?

Corbus Pharmaceuticals Holdings is in the Biotechnology industry

What country is Corbus Pharmaceuticals Holdings from?

Corbus Pharmaceuticals Holdings is headquartered in United States

When did Corbus Pharmaceuticals Holdings go public?

Corbus Pharmaceuticals Holdings initial public offering (IPO) was on 27 October 2014

What is Corbus Pharmaceuticals Holdings website?

https://www.corbuspharma.com

Is Corbus Pharmaceuticals Holdings in the S&P 500?

No, Corbus Pharmaceuticals Holdings is not included in the S&P 500 index

Is Corbus Pharmaceuticals Holdings in the NASDAQ 100?

No, Corbus Pharmaceuticals Holdings is not included in the NASDAQ 100 index

Is Corbus Pharmaceuticals Holdings in the Dow Jones?

No, Corbus Pharmaceuticals Holdings is not included in the Dow Jones index

When was Corbus Pharmaceuticals Holdings the previous earnings report?

No data

When does Corbus Pharmaceuticals Holdings earnings report?

The next expected earnings date for Corbus Pharmaceuticals Holdings is 07 November 2024